{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:30:27Z","timestamp":1787059827621,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jns.2026.125950","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:30:19Z","timestamp":1777332619000},"page":"125950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on \u201cOcrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis\u201d"],"prefix":"10.1016","volume":"487","author":[{"given":"Abhishek","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srishti","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125950_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.125693","article-title":"Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis","volume":"480","author":"Rangani","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125950_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13297-5","article-title":"First the b cells fall, then the t cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis","author":"Abbadessa","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.125950_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/sclerosis3040035","article-title":"Evaluation of early initiation of disease-modifying treatment for patients with multiple sclerosis within a real-world population for long-term outcomes","volume":"3","author":"McDonald","year":"2025","journal-title":"Sclerosis"},{"key":"10.1016\/j.jns.2026.125950_bb0020","series-title":"Housekeeping Gene and its Internal Control","year":"2025"},{"key":"10.1016\/j.jns.2026.125950_bb0025","series-title":"Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple Sclerosis","author":"Curtin","year":"2025"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:15:06Z","timestamp":1787058906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26002327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"alternative-id":["S0022510X26002327"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125950","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cOcrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125950"}}